-
06:19:46 PM

AURA Stock News

03/15/23 4:10 PM
Nasdaq : AURA
earningsclinical triallow float
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights. Cadmus Rich, Chief Medical Officer of...
RHEA-AI
very positive
02/16/23 7:00 AM
Nasdaq : AURA
clinical triallow float
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
Aura Biosciences, Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the presentation of positive interim Phase 2 safety and efficacy data of bel-sar with 9-10 months of follow up evaluating two key clinical endpoints: tumor control and visual...
RHEA-AI
neutral
11/10/22 7:00 AM
Nasdaq : AURA
earningsclinical triallow float
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the third quarter ended September 30, 2022 and provided clinical development and operational highlights. “We are encouraged by the meaningful clinical...
RHEA-AI
neutral
11/10/22 6:45 AM
Nasdaq : AURA
clinical triallow float
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that it has initiated startup activities for the global Phase 3 trial. Cadmus Rich, Chief Medical Officer of Aura Biosciences.“ We are pleased to have aligned with regulatory...
RHEA-AI
very positive
10/03/22 7:00 AM
Nasdaq : AURA
clinical triallow float
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented at AAO 2022
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced that interim Phase 2 data evaluating the safety and efficacy of suprachoroidal administration using its first VDC product candidate, belzupacap sarotalocan, for the...
RHEA-AI
neutral
09/28/22 7:00 AM
Nasdaq : AURA
clinical triallow float
Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
Aura Biosciences Inc., a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1 study evaluating belzupacap sarotalocan, the Company’ s first VDC product candidate, for the treatment of Non-Muscle Invasive...
RHEA-AI
neutral